

Nikhil Yawalkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7192742/publications.pdf>

Version: 2024-02-01

84
papers

4,747
citations

87723

38
h-index

102304

66
g-index

92
all docs

92
docs citations

92
times ranked

4422
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience. <i>Dermatology</i> , 2022, 238, 267-275.	0.9	10
2	Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 675-683.	0.6	5
3	The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B/apolipoprotein A-1 ratio. <i>Arthritis Research and Therapy</i> , 2022, 24, 17.	1.6	5
4	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
5	MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in Psoriasis. <i>Frontiers in Medicine</i> , 2022, 9, 869912.	1.2	5
6	Sex-differential downregulation of methotrexate on plasma viscosity and whole blood viscosity in psoriasis. <i>Clinical Hemorheology and Microcirculation</i> , 2022, , 1-10.	0.9	0
7	<scpi>iTRAQ</scpi>-based quantitative proteomics reveals biomarkers/pathways in psoriasis that can predict the efficacy of methotrexate. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1784-1795.	1.3	6
8	New onset of sarcoidosis after <scpi>COVID</scpi>-19 infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	4
9	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€œ Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 281-317.	1.3	84
10	The Impact of ANXA6 Gene Polymorphism on the Efficacy of Methotrexate Treatment in Psoriasis Patients. <i>Dermatology</i> , 2021, 237, 579-587.	0.9	8
11	TineaÂ° Corporis with Trichophyton Rubrum Mimicking a Flare-Up of Psoriasis Under Treatment with IL17-Inhibitor Ixekizumab. <i>Case Reports in Dermatology</i> , 2021, 13, 347-351.	0.3	4
12	Identification of proteins associated with development of psoriatic arthritis in peripheral blood mononuclear cells: a quantitative iTRAQ-based proteomics study. <i>Journal of Translational Medicine</i> , 2021, 19, 331.	1.8	8
13	New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e752-e755.	1.3	31
14	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. <i>Dermatology</i> , 2021, 237, 166-178.	0.9	17
15	Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1003-1014.e8.	0.3	25
16	IgA Triggers Cell Death of Neutrophils When Primed by Inflammatory Mediators. <i>Journal of Immunology</i> , 2020, 205, 2640-2648.	0.4	4
17	Successful treatment of refractory folliculitis decalvans with apremilast. <i>JAAD Case Reports</i> , 2020, 6, 1079-1081.	0.4	5
18	Herpetiform aphthous ulcerations induced by secukinumab: Report of 2 cases. <i>JAAD Case Reports</i> , 2020, 6, 1107-1109.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine. <i>JAAD Case Reports</i> , 2020, 6, 634-636.	0.4	7
20	Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils. <i>Frontiers in Immunology</i> , 2020, 11, 973.	2.2	4
21	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2461-2498.	1.3	149
22	Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). <i>Archives of Dermatological Research</i> , 2019, 311, 753-760.	1.1	11
23	Infliximab reduces activated myeloid dendritic cells, different macrophage subsets and CXCR 3-positive cells in granuloma annulare. <i>Journal of Dermatology</i> , 2019, 46, 808-811.	0.6	8
24	Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2313-2318.	1.3	2
25	Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis. <i>New England Journal of Medicine</i> , 2019, 381, 1975-1977.	13.9	14
26	Effects of Omalizumab on Fc̑RI and IgE Expression in Lesional Skin of Bullous Pemphigoid. <i>Frontiers in Immunology</i> , 2019, 10, 1919.	2.2	32
27	Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis. <i>JAMA Dermatology</i> , 2019, 155, 327.	2.0	19
28	Human T _H 9 cells are a subpopulation of PPAR-̒ T _H 2 cells. <i>Science Immunology</i> , 2019, 4, .	5.6	75
29	IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1732-1742.e17.	0.3	42
30	TT genotype of rs10036748 in TNIP1 shows better response to methotrexate in a Chinese population: a prospective cohort study. <i>British Journal of Dermatology</i> , 2019, 181, 778-785.	1.4	15
31	Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 848-858.	0.3	43
32	Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 700-708.	1.3	78
33	Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e256-e257.	1.3	27
34	Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response. <i>Experimental Dermatology</i> , 2018, 27, 172-177.	1.4	45
35	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. <i>Cell Reports</i> , 2018, 25, 3564-3572.e4.	2.9	49
36	Interleukin 23 – Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. <i>JAMA Dermatology</i> , 2017, 153, 304.	2.0	111

#	ARTICLE	IF	CITATIONS
37	Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. <i>Clinical Rheumatology</i> , 2017, 36, 2035-2043.	1.0	8
38	Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1189-1191.	0.6	41
39	Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2091-2096.	1.3	56
40	Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2017, 177, 1358-1366.	1.4	40
41	Apremilast for treatment of recalcitrant aphthous stomatitis. <i>JAAD Case Reports</i> , 2017, 3, 410-411.	0.4	14
42	Swiss S1 guideline for the treatment of rosacea. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1775-1791.	1.3	50
43	Canakinumab for Severe Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2017, 153, 1195.	2.0	45
44	Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 371-393.	2.9	52
45	Generalized Comedones, Acne, and Hidradenitis Suppurativa in a Patient with an FGFR2 Missense Mutation. <i>Frontiers in Medicine</i> , 2017, 4, 16.	1.2	24
46	Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1214.	1.8	131
47	IgE and FcÎµR1 are highly expressed on innate cells in psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 122-133.	1.4	17
48	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. <i>Dermatology</i> , 2016, 232, 385-406.	0.9	39
49	Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 81-87.e1.	0.6	27
50	Canakinumab in adults with steroid-refractory pyoderma gangrenosum. <i>British Journal of Dermatology</i> , 2015, 173, 1216-1223.	1.4	95
51	Homozygous Missense Mutation in IL36RN in Generalized Pustular Dermatitis With Intraoral Involvement Compatible With Both AGEF and Generalized Pustular Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 452.	2.0	44
52	European S3 Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	1.3	353
53	Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. <i>Archives of Dermatological Research</i> , 2014, 306, 933-938.	1.1	49
54	Human T _H 9 Cells Are Skin-Tropic and Have Autocrine and Paracrine Proinflammatory Capacity. <i>Science Translational Medicine</i> , 2014, 6, 219ra8.	5.8	172

#	ARTICLE	IF	CITATIONS
55	Increased expression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 683-690.e1.	0.6	34
56	Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis. <i>Case Reports in Dermatology</i> , 2013, 5, 332-335.	0.3	15
57	Cytokines and Chemokines in Irritant Contact Dermatitis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-7.	1.4	85
58	Rapid Downregulation of Innate Immune Cells, Interleukin-12 and Interleukin-23 in Generalized Pustular Psoriasis with Infliximab in Combination with Acitretin. <i>Dermatology</i> , 2012, 225, 338-343.	0.9	13
59	Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 790-798.	0.6	326
60	NKp46 ⁺ cells express granulysin in multiple cutaneous adverse drug reactions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1469-1476.	2.7	45
61	<i>In vitro</i> detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 376-384.	2.7	74
62	Characterization of dendritic cells and macrophages in irritant contact dermatitis. <i>Journal of Dermatological Science</i> , 2010, 57, 216-218.	1.0	4
63	DRUG HYPERSENSITIVITY. <i>Acta Clinica Belgica</i> , 2009, 64, 529-533.	0.5	7
64	Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. <i>Journal of Dermatological Science</i> , 2009, 54, 99-105.	1.0	93
65	Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. <i>British Journal of Dermatology</i> , 2008, 158, 691-697.	1.4	110
66	Maculopapular Drug Eruptions. , 2007, , 242-250.		11
67	Oral Prednisolone Induced Acute Generalized Exanthematous Pustulosis due to Corticosteroids of Group A Confirmed by Epicutaneous Testing and Lymphocyte Transformation Tests. <i>Dermatology</i> , 2006, 213, 40-43.	0.9	45
68	Drug-induced exanthems. <i>Toxicology</i> , 2005, 209, 131-134.	2.0	56
69	Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. <i>Archives of Dermatological Research</i> , 2005, 296, 503-506.	1.1	56
70	Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. <i>British Journal of Dermatology</i> , 2004, 151, 903-906.	1.4	57
71	Acute Generalized Exanthematous Pustulosis. <i>American Journal of Pathology</i> , 2002, 161, 2079-2086.	1.9	145
72	Immunohistology of drug-induced exanthema: clues to pathogenesis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 299-303.	1.1	28

#	ARTICLE	IF	CITATIONS
73	CD1a-positive dendritic cells transport the antigen DNCB intracellularly from the skin to the regional lymph nodes in the induction phase of allergic contact dermatitis. Archives of Dermatological Research, 2001, 293, 420-426.	1.1	11
74	T cell involvement in cutaneous drug eruptions. Clinical and Experimental Allergy, 2001, 31, 1398-1408.	1.4	174
75	Pathogenesis of Drug-Induced Exanthema. International Archives of Allergy and Immunology, 2001, 124, 336-338.	0.9	23
76	T-cell involvement in drug-induced acute generalized exanthematous pustulosis. Journal of Clinical Investigation, 2001, 107, 1433-1441.	3.9	314
77	T Cells Isolated from Positive Epicutaneous Test Reactions to Amoxicillin and Ceftriaxone are Drug Specific and Cytotoxic. Journal of Investigative Dermatology, 2000, 115, 647-652.	0.3	84
78	Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clinical and Experimental Allergy, 2000, 30, 847-855.	1.4	158
79	Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitis. Journal of Allergy and Clinical Immunology, 2000, 106, 941-947.	1.5	27
80	Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. Journal of Allergy and Clinical Immunology, 2000, 106, 1171-1176.	1.5	118
81	Distinct Serum Cytokine Levels in Drug- and Measles-Induced Exanthema. International Archives of Allergy and Immunology, 1999, 120, 225-229.	0.9	52
82	Expression of Interleukin-12 is Increased in Psoriatic Skin. Journal of Investigative Dermatology, 1998, 111, 1053-1057.	0.3	185
83	T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clinical and Experimental Allergy, 1998, 28, 1412-1417.	1.4	133
84	Elevated serum levels of interleukins 5, 6, and 10 in a patient with drug-induced exanthem caused by systemic corticosteroids. Journal of the American Academy of Dermatology, 1998, 39, 790-793.	0.6	25